The FDA has granted accelerated approval to sevabertinib (Hyrnuo), for previously treated HER+ metastatic non-squamous ...
The FDA has approved epcoritamab-bysp (Epkinly) with rituximab and lenalidomide for relapsed or refractory follicular ...
The FDA has approved ziftomenib (KOMZIFTI), the first oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia (AML). In the KOMET-001 trial, the therapy ...
Novartis has opened a new 10,000-square-foot radioligand therapy (RLT) manufacturing facility in Carlsbad, California, ...
Results from the phase II LenCabo trial show that lenvatinib plus everolimus significantly prolonged progression-free ...
Findings from the DYNAMIC-III trial, show that ctDNA testing can transform post-surgical care in Stage III colon cancer. Among more than 1,000 patients, ctDNA-negative individuals achieved 87% ...
New data from the phase 1b DeLLphi-303 study show that adding tarlatamab to first-line chemoimmunotherapy achieved a 71% ...
ESMO’s new ELCAP guidance, published in Annals of Oncology, distills 23 consensus statements from 20 experts to safely integrate large language models into cancer care. It categorizes LLMs as ...
Five-year data from the Phase III NATALEE trial confirm that adjuvant ribociclib (Kisqali) plus endocrine therapy reduces ...
Researchers at CiQUS have developed self-assembling peptide nanotubes that deliver doxorubicin directly into the nucleus of drug-resistant cancer cells, restoring the chemotherapy’s potency. The ...
A new study published in Science Advances reveals a groundbreaking approach that makes cancer cells turn against themselves by reprogramming how they die. Scientists at the Institut Pasteur and Inserm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback